Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into ...

Today, the value of this approach is widely recognised even by most pharmaceutical companies, a number of which – including Sanofi, Roche and Genentech, Bayer, and Merck KgaA – have partnered with ...

Recursion Pharmaceuticals (RXRX 0.02%), a biotech company focused on artificial intelligence (AI), went public in April 2021. This was before ChatGPT, before AI became the hottest ...

Self-Referential Large Models: Recursive Self-Enhancement in Code Generation ...

Recursion will also receive an additional $30 million upfront payment from Bayer to develop new treatments for chronic scar tissue, or fibrotic, diseases of the lung, kidneys and heart.

Rallybio (RLYB) announced that it received an equity milestone payment of $12.5M from Recursion Pharmaceuticals (RXRX). The milestone payment was ...

The most profound failures in history are not those that bet big and lost, but those that failed to bet at all. Incremental advances will never cure Alzheimer’s disease or reverse climate change. To ...

Few movie moments match the spinning top in Inception, which left audiences questioning reality. Christopher Nolan’s 2010 ...

New research explores how prolonged AI interactions can, at least for some users, start to blur the lines between reality and fantasy. Simple interventions could prevent tragic outcomes.

Absci's AI-driven drug discovery platform, its potential, challenges, and strategic partnerships. Read here for an investment analysis of ABSI stock.